Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet

Journal of Virology

Volumn 80, Issue 3, 2006, Pages 1440-1450

  Tchesnokov, Egor P ^a,b   Gilbert, Christian ^c   Boivin, Guy ^c   Götte, Matthias ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DNA POLYMERASE; FOSCARNET; PYROPHOSPHORIC ACID DERIVATIVE;

AMINO ACID ANALYSIS; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CRYSTAL STRUCTURE; CYTOMEGALOVIRUS; DISEASE PREDISPOSITION; GENE MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SUBSTITUTION REACTION; VIRUS RESISTANCE; WILD TYPE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ANTIVIRAL AGENTS; BASE SEQUENCE; BINDING SITES; CYTOMEGALOVIRUS; DIPHOSPHATES; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; FOSCARNET; HUMANS; KINETICS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PROTEIN STRUCTURE, SECONDARY; RABBITS; SEQUENCE HOMOLOGY, AMINO ACID;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 31144436564     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.80.3.1440-1450.2006     Document Type: Article

References (42)

1. Bestman-Smith, J., and G. Boivin. 2003. Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids. J. Virol. 77:7820-7829.
2. Boosalis, M. S., J. Petruska, and M. F. Goodman. 1987. DNA polymerase insertion fidelity. Gel assay for site-specific kinetics. J. Biol. Chem. 262:14689-14696.
3. Chou, S., N. S. Lurain, K. D. Thompson, R. C. Miner, and W. L. Drew. 2003. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis. 188:32-39.
4. Chou, S. W. 2001. Cytomegalovirus drug resistance and clinical implications. Transpl. Infect. Dis. 3(Suppl. 2):20-24.
5. Cihlar, T., M. D. Fuller, and J. M. Cherrington. 1998. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J. Virol. 72:5927-5936.
6. Cihlar, T., M. D. Fuller, and J. M. Cherrington. 1997. Expression of the catalytic subunit (UL54) and the accessory protein (UL44) of human cytomegalovirus DNA polymerase in a coupled in vitro transcription/translation system. Protein Expr. Purif. 11:209-218.
7. Cihlar, T., M. D. Fuller, A. S. Mulato, and J. M. Cherrington. 1998. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. Virology 248:382-393.
8. Crumpacker, C. S. 1992. Mechanism of action of foscarnet against viral polymerases. Am. J. Med. 92:3S-7S.
9. De Clercq, E. 2004. Antiviral drugs in current clinical use. J. Clin. Virol. 30:115-133.
10. Derse, D., K. F. Bastow, and Y. Cheng. 1982. Characterization of the DNA polymerases induced by a group of herpes simplex virus type I variants selected for growth in the presence of phosphonoformic acid. J. Biol. Chem. 257:10251-10260.
11. Drew, W. L., C. V. Paya, and V. Emery. 2001. Cytomegalovirus (CMV) resistance to antivirals. Am. J. Transplant. 1:307-312.
12. Erice, A. 1999. Resistance of human cytomegalovirus to antiviral drugs. Clin. Microbiol. Rev. 12:286-297.
13. Eriksson, B., B. Oberg, and B. Wahren. 1982. Pyrophosphate analogues as inhibitors of DNA polymerases of cytomegalovirus, herpes simplex virus and cellular origin. Biochim. Biophys. Acta 696:115-123.
14. Franklin, M. C., J. Wang, and T. A. Steitz. 2001. Structure of the replicating complex of a pol alpha family DNA polymerase. Cell 105:657-667.
15. Freisinger, E., A. P. Grollman, H. Miller, and C. Kisker. 2004. Lesion (in)tolerance reveals insights into DNA replication fidelity. EMBO J. 23:1494-1505.
16. Gandhi, M. K., and R. Khanna. 2004. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect. Dis. 4:725-738.
17. Gilbert, C., J. Bestman-Smith, and G. Boivin. 2002. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist. Updates 5:88-114.
18. Gilbert, C., and G. Boivin. 2005. Human cytomegalovirus resistance to antiviral drugs. Antimicrob. Agents Chemother. 49:873-883.
19. Hall, J. D., and S. Woodward. 1989. Aphidicolin resistance in herpes simplex virus type 1 appears to alter substrate specificity in the DNA polymerase. J. Virol. 63:2874-2876.
20. Hogg, M., S. S. Wallace, and S. Doublie. 2004. Crystallographic snapshots of a replicative DNA polymerase encountering an abasic site. EMBO J. 23:1483-1493.
21. Hsiou, Y., J. Ding, K. Das, A. D. Clark, Jr., P. L. Boyer, P. Lewi, P. A. Janssen, J. P. Kleim, M. Rosner, S. H. Hughes, and E. Arnold. 2001. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J. Mol. Biol. 309:437-445.
22. Huang, L., K. K. Ishii, H. Zuccola, A. M. Gehring, C. B. Hwang, J. Hogle, and D. M. Coen. 1999. The enzymological basis for resistance of herpesvirus DNA polymerase mutants to acyclovir: relationship to the structure of alpha-like DNA polymerases. Proc. Natl. Acad. Sci. USA 96:447-452.
23. Landolfo, S., M. Gariglio, G. Gribaudo, and D. Lembo. 2003. The human cytomegalovirus. Pharmacol. Ther. 98:269-297.
24. Loregian, A., B. A. Appleton, J. M. Hogle, and D. M. Coen. 2004. Specific residues in the connector loop of the human cytomegalovirus DNA polymerase accessory protein UL44 are crucial for interaction with the UL54 catalytic subunit. J. Virol. 78:9084-9092.
25. Marchand, B., and M. Gotte. 2003. Site-specific footprinting reveals differences in the translocation status of HIV-1 reverse transcriptase. Implications for polymerase translocation and drug resistance. J. Biol. Chem. 278:35362-35372.
26. Meyer, P. R., S. E. Matsuura, D. Zonarich, R. R. Chopra, E. Pendarvis, H. Z. Bazmi, J. W. Mellors, and W. A. Scott. 2003. Relationship between 3′-azido-3′-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 77:6127-6137.
27. Morphin, F., and D. Thouvenot. 2003. Herpes simplex virus resistance to antiviral drugs. J. Clin. Virol. 26:29-37.
28. Oberg, B. 1982. Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacol. Ther. 19:387-415.
29. Reardon, J. E., and W. H. Miller. 1990. Human immunodeficiency virus reverse transcriptase. Substrate and inhibitor kinetics with thymidine 5′-triphosphate and 3′-azido-3′-deoxythymidine 5′-triphosphate. J. Biol. Chem. 265:20302-20307.
30. i analog phosphonoacetic acid. J. Virol. 67:60-66.
31. Sluis-Cremer, N., D. Arion, N. Kaushik, H. Lim, and M. A. Parniak. 2000. Mutational analysis of Lys65 of HIV-1 reverse transcriptase. Biochem. J. 348:77-82.
32. Smith, I. L., J. M. Cherrington, R. E. Jiles, M. D. Fuller, W. R. Freeman, and S. A. Spector. 1997. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J. Infect. Dis. 176:69-77.
33. Springer, K. L., and A. Weinberg. 2004. Cytomegalovirus infection in the era of HAART: fewer reactivations and more immunity. J. Antimicrob. Chemother. 54:582-586.
34. Thomsen, D. R., N. L. Oien, T. A. Hopkins, M. L. Knechtel, R. J. Brideau, M. W. Wathen, and F. L. Homa. 2003. Amino acid changes within conserved region III of the herpes simplex virus and human cytomegalovirus DNA polymerases confer resistance to 4-oxo-dihydroquinolines, a novel class of herpesvirus antiviral agents. J. Virol. 77:1868-1876.
35. Tsurumi, T., K. Maeno, and Y. Nishiyama. 1987. A single-base change within the DNA polymerase locus of herpes simplex virus type 2 can confer resistance to aphidicolin. J. Virol. 61:388-394.
36. Wang, J., A. K. Sattar, C. C. Wang, J. D. Karam, W. H. Konigsberg, and T. A. Steitz. 1997. Crystal structure of a pol alpha family replication DNA polymerase from bacteriophage RB69. Cell 89:1087-1099.
37. Weinberg, A., D. A. Jabs, S. Chou, B. K. Martin, N. S. Lurain, M. S. Forman, and C. Crumpacker. 2003. Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J. Infect. Dis. 187:777-784.
38. Xiong, X., J. L. Smith, and M. S. Chen. 1997. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob. Agents Chemother. 41:594-599.
39. Xiong, X., J. L. Smith, C. Kim, E. S. Huang, and M. S. Chen. 1996. Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase. Biochem. Pharmacol. 51:1563-1567.
40. Yang, G., M. Franklin, J. Li, T. C. Lin, and W. Konigsberg. 2002. Correlation of the kinetics of finger domain mutants in RB69 DNA polymerase with its structure. Biochemistry 41:2526-2534.
41. Ye, L. B., and E. S. Huang. 1993. In vitro expression of the human cytomegalovirus DNA polymerase gene: effects of sequence alterations on enzyme activity. J. Virol. 67:6339-6347.
42. Yin, Y. W., and T. A. Steitz. 2004. The structural mechanism of translocation and helicase activity in T7 RNA polymerase. Cell 116:393-404.